Chugh Shaan, Suen Colin, Gramolini Anthony
Department of Physiology, University of Toronto.
Curr Cardiol Rev. 2010 May;6(2):124-33. doi: 10.2174/157340310791162631.
The emergence of new platforms for the discovery of innovative therapeutics has provided a means for diagnosing cardiac disease in its early stages. Taking into consideration the global health burden of cardiac disease, clinicians require innovations in medical diagnostics that can be used for risk stratification. Proteomic based studies offer an avenue for the discovery of proteins that are differentially regulated during disease; such proteins could serve as novel biomarkers of the disease state. For instance, in clinical practice, the abundance of such biomarkers in blood could be correlated with the severity of the disease state. As such, early detection of biomarkers would enable an improvement in patient prognosis. In this review, we outline advancements in various proteomic platforms used to study the disease proteome and their applications to the field of clinical medicine. Specifically, we highlight the contributions of proteomic-based profiling experiments to the analysis of cardiovascular diseases.
用于发现创新疗法的新平台的出现为早期诊断心脏病提供了一种手段。考虑到心脏病的全球健康负担，临床医生需要可用于风险分层的医学诊断创新方法。基于蛋白质组学的研究为发现疾病期间差异调节的蛋白质提供了一条途径；此类蛋白质可作为疾病状态的新型生物标志物。例如，在临床实践中，血液中此类生物标志物的丰度可能与疾病状态的严重程度相关。因此，生物标志物的早期检测将改善患者的预后。在本综述中，我们概述了用于研究疾病蛋白质组的各种蛋白质组学平台的进展及其在临床医学领域的应用。具体而言，我们强调了基于蛋白质组学的分析实验对心血管疾病分析的贡献。
